Alvotech And Cipla Expand Biosimilars Deal For Australia And New Zealand
After Partnering On Multiple Biosimilars In South Africa And Emerging Markets
Cipla has expanded its partnership with Alvotech to cover the commercialization of four biosimilars in Australia and New Zealand, building on an existing alliance covering South Africa and emerging markets.
You may also be interested in...
Alvotech has completed a $100m private placement after concluding a second found of funding worth $35m. The move comes as the company prepares to commercialize its portfolio of biosimilars through a series of partnerships.
Plus deals involving WuXi AppTec/OXGENE, Oscotec/Beatica, ReViral/LianBio, Wugen/HCW Biologics, Starton/Haisco, Shanghai Junshi/AstraZeneca, HitGen/Uppthera, Bridge/LegoChem, Macrogen/Lifex, BeiGene/Boston Immune
As Alvotech advances towards launches around the world for its portfolio of biosimilars, the firm is ramping up capacity at its Reykjavik facility.